Linzagolix

SAN DIEGO — Several abstracts were presented at the ACOG Annual Clinical & Scientific Meeting on the efficacy and safety of linzagolix, an investigational oral GnRH antagonist being developed for the treatment of fibroid-related symptoms.

Linzagolix reduced uterine and fibroid volumes and improved pain and hemoglobin levels in women with uterine fibroids, according to multiple analyses of two phase 3 clinical trials.